RSP Systems (RSP), the company developing what it's calling the world’s first universal non-invasive glucose monitoring wearable, has had the results of a key study published by Nature Scientific Reports (Nature) demonstrating successful pre-trained calibration and continual non-invasive glucose monitoring in patients with type 2 diabetes using RSP’s GlucoBeam Smart technology.
The study, entitled “Calibration and performance of a Raman-based device for non-invasive glucose monitoring in type 2 diabetes”, involved 50 people with type 2 diabetes over a two day period. The patients were intentionally diverse with respect to age, BMI, duration of diabetes, HbA1c, and form of therapy to cover a wide spectrum for testing the performance of the device.
Patients were monitored using RSP’s GlucoBeam Smart technology which measures skin glucose using light only. The reflected light was analyzed to establish levels of glucose. The recorded data was compared to traditional blood sample testing via a finger prick test and showed that it was comparable with respect to numerical and clinical accuracy.
The key part of the study was the calibration step for each individual via direct electronic model transfer. Previous studies have required a significant level of pre-testing calibration, in some cases for several weeks. In this study, comparable results were achieved with a calibration period of less than 4 hours. To date, achieving this level of information transfer has been a major obstacle to industrial standardization, production and commercial scalability.
